Follicular Lymphoma

Featured

Quiz
Quiz: Does Rituximab Added to Chemotherapy Improve PFS and OS in FL?
True or False: The addition of rituximab to anthracycline-based chemotherapy improves PFS and OS in FL.
Conference Coverage
Rituximab Monotherapy Extends TTNT vs Observation in Advanced FL
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage…
Conference Coverage
Adding Rituximab to Anthracycline-Based Chemotherapy Increases PFS, OS in FL
The addition of rituximab to anthracycline-based chemotherapy demonstrates improved PFS and OS in FL, according to a 35…
Conference Coverage
Watch and Wait vs Initial Treatment for Advanced FL
Study findings show patients with advanced FL who received initial treatment had better OS compared to those managed…
Conference Coverage
Treatment Sequencing Impact on Outcomes and Costs in Relapsed/Refractory FL
The use of 90 Y-ibritumomab tiuxetan in consolidation or second-line treatment of relapsed or refractory FL…

News

Obinutuzumab- and Rituximab-Based Chemo Improve HRQoL in Advanced FL
Study Reviews Cost-Effectiveness, Costs and Resource Use, and HRQoL in FL and MZL
High Economic Burden of FL Climbs Through Additional Lines of Therapy
Examining Bone Marrow Biopsies for Response Assessment in Follicular Lymphoma Clinical Trials

Guideline Updates

NCCN B-Cell Lymphomas Guideline Features Therapy Updates in Follicular Lymphoma, DLBCL

Interviews

Challenges of Managing Follicular Lymphoma: A Focus on PI3K Inhibitors and Next-Line Therapy

Videos

Study Highlights Need to Minimize Health Care Costs in FL

Podcast

Treatment Options for Patients With Relapsed/Refractory FL